调节你的坐时间 (RESIT) 干预措施,以减少2型糖尿病患者的坐时间:随机对照可行性试验的结果
Marsha L Brierley1,2, Angel M Chater3,4, Charlotte L Edwardson5,6
1Centre for Physical Activity in Health and Disease, College of Health, Medicine and Life Sciences, Brunel University London, Kingston Lane, UB8 3PH, Uxbridge, UK.
Diabetology & metabolic syndrome
|April 24, 2024
概括
这项研究表明,REgulate your Sitting Time (RESIT) 在线计划是帮助患有2型糖尿病的成年人减少久坐时间的可行和可接受的方式. 进一步的试验现在可以评估其在治疗糖尿病方面的临床有效性.
科学领域:
- 临床医学 临床医学
- 公共卫生 公共卫生
- 行为科学 行为科学
背景情况:
- 减少久坐不动的行为对于管理2型糖尿病 (T2DM) 至关重要.
- 针对针对T2DM个体减少坐着时间的干预措施的证据有限.
- 这项研究评估了量身定制的在线干预措施的可行性和可接受性,以减少和中断T2DM成年人的坐姿.
研究的目的:
- 为了评估REgulate your SItting Time (RESIT) 在线干预的可行性和可接受性.
- 评估最终试验的招聘,保留和数据完成率.
- 探索参与者对干预和试验程序的经验.
主要方法:
- 一个混合方法,双臂随机对照可行性试验.
- 患有T2DM的参与者被随机分配到RESIT干预 (在线教育,自我监测,健康指导) 或常规护理.
- 可行性结果包括招聘,消耗,数据完整性和可接受性;数量和质量数据在6个月内收集.
主要成果:
- 招募了70名参与者 (55±11岁),招募率为67%,在6个月后保留率为93%.
- 观察到高数据完成率 (83-91%). 描述性分析表明,干预组的装置测量坐时间可能减少.
- 定性分析显示了参与者的积极经验以及干预和研究程序的可接受性.
结论:
- 对于患有T2DM的成年人来说,RESIT干预和评估方法是可行的和可以接受的.
- 这些发现支持进行最终试验,以确定 RESIT 的临床有效性.
- 成功实施RESIT可以通过优先考虑减少坐时间来影响糖尿病医疗保健.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Management and Pharmacotherapy
268
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
268
Insulin: Dosing Regimen and Adverse Effects
168
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
168
Carbohydrate Metabolism
11.1K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K


